全文获取类型
收费全文 | 29748篇 |
免费 | 2160篇 |
国内免费 | 262篇 |
专业分类
耳鼻咽喉 | 435篇 |
儿科学 | 504篇 |
妇产科学 | 650篇 |
基础医学 | 4321篇 |
口腔科学 | 739篇 |
临床医学 | 2640篇 |
内科学 | 5841篇 |
皮肤病学 | 601篇 |
神经病学 | 2178篇 |
特种医学 | 1654篇 |
外科学 | 4786篇 |
综合类 | 357篇 |
一般理论 | 11篇 |
预防医学 | 1274篇 |
眼科学 | 714篇 |
药学 | 2552篇 |
1篇 | |
中国医学 | 282篇 |
肿瘤学 | 2630篇 |
出版年
2023年 | 151篇 |
2022年 | 322篇 |
2021年 | 799篇 |
2020年 | 452篇 |
2019年 | 750篇 |
2018年 | 804篇 |
2017年 | 666篇 |
2016年 | 765篇 |
2015年 | 1119篇 |
2014年 | 1374篇 |
2013年 | 1545篇 |
2012年 | 2362篇 |
2011年 | 2313篇 |
2010年 | 1419篇 |
2009年 | 1303篇 |
2008年 | 1833篇 |
2007年 | 1743篇 |
2006年 | 1637篇 |
2005年 | 1577篇 |
2004年 | 1409篇 |
2003年 | 1219篇 |
2002年 | 1105篇 |
2001年 | 854篇 |
2000年 | 806篇 |
1999年 | 647篇 |
1998年 | 234篇 |
1997年 | 219篇 |
1996年 | 184篇 |
1995年 | 160篇 |
1994年 | 133篇 |
1993年 | 110篇 |
1992年 | 258篇 |
1991年 | 199篇 |
1990年 | 197篇 |
1989年 | 186篇 |
1988年 | 159篇 |
1987年 | 121篇 |
1986年 | 110篇 |
1985年 | 75篇 |
1984年 | 88篇 |
1983年 | 59篇 |
1982年 | 57篇 |
1981年 | 52篇 |
1980年 | 50篇 |
1979年 | 59篇 |
1978年 | 48篇 |
1977年 | 50篇 |
1976年 | 44篇 |
1972年 | 48篇 |
1971年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
Autoimmune comorbid diseases associated with lichen planus: a nationwide case–control study
下载免费PDF全文
![点击此处可从《Journal of the European Academy of Dermatology and Venereology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
3.
4.
5.
6.
Xin Yi Wong Andrew Qi Jun Lim Qianyu Shen John Whay Kuang Chia Min Hoe Chew Wah Siew Tan 《Current medical research and opinion》2020,36(10):1677-1686
Abstract
Objective
Ras wild-type metastatic colorectal cancers (mCRC) may be treated with anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor (EGFR) agents. We aim to estimate patients’ preferences for mCRC treatment and relative importance of cost, efficacy improvement, avoidance of side effects and therapy convenience, and relative uptake between profiles that resemble Bevacizumab (anti-VEGF) and Cetuximab (anti-EGFR), two commonly prescribed mCRC targeted therapies. 相似文献7.
Matrine,oxymatrine, and compound Kushen injection from the roots of Sophora flavescens: an overview of their anticancer activities
下载免费PDF全文
![点击此处可从《中国药学》网站下载免费的PDF全文](/ch/ext_images/free.gif)
In the present review, we updated current information on the chemistry, contents, and anticancer properties of matrine (MT), oxymatrine (OMT), and compound Kushen injection (CKI). The anticancer properties were focused on lung, breast, and liver cancer cells because they are most susceptible. Sources of information were from Google, Google Scholar, PubMed, PubMed Central, Science Direct, PubChem, J-Stage, Directory of Open Access Journals (DOAJ), and China National Knowledge Infrastructure (CNKI). Reference was also made on botanical websites, such as Flora of China and World Flora Online. MT and OMT are dominant quinolizidine alkaloids from the roots of Sophora flavescens (Kushen) of the family Fabaceae. Against lung, breast, and liver cancer cells, MT and OMT inhibit cell proliferation; induce cell cycle arrest, apoptosis, and autophagy; restrict angiogenesis; and inhibit cell metastasis, invasion, and migration. The processes involve various molecular targets and signaling pathways. CKI is a traditional Chinese medicine (TCM) composed of root extracts of S. flavescens and Smilax glabra (Baituling) of the family Smilacaceae. With MT and OMT as major components, CKI has been approved for the treatment of cancer in China more than 20 years ago. In recent years, systematic reviews and meta-analysis have been undertaken to evaluate the anticancer effects of CKI. When CKI is used alone and in combination with chemotherapy of western medicine, there is much to be learned concerning their interactions besides their individual and integrated efficacy. Some perspectives of MT, OMT, and CKI are discussed, and their suggestions for future research are provided. 相似文献
8.
Jim Zhong Michael Gallagher Chris Hounslow Gareth Iball Tze Wah 《Diagnostic and interventional radiology (Ankara, Turkey)》2021,27(2):244
PURPOSEWe aimed to evaluate the effect on the radiation dose to the patient by reducing the tube current during the placement of the ablation needles (reduced dose group) compared with the patient doses delivered when scanning at the standard fully diagnostic level (full dose group) in computed tomography (CT)-guided percutaneous cryoablation.METHODSWe conducted a retrospective study of 103 patients undergoing cryoablation in a tertiary cancer center. Overall, 62 patients were scanned with standard exposure parameters (full dose group) set on a 64-slice multidetector CT scanner, while 41 patients were scanned on a reduced dose protocol. Dose levels were retrieved from the hospital picture and archiving communication system including the volumetric CT dose index (CTDIvol), total dose length product (DLP), length of cryoablation procedure, number of cryoablation needles and patient size. Wilcoxon Mann-Whitney (rank-sum) tests were used to compare the median DLP, CTDIvol and skin dose between the two groups.RESULTSMedian total DLP for the full dose group was 6025 mGy·cm (1909–13353 mGy·cm) compared with 3391 mGy·cm (1683–6820 mGy·cm) for the reduced dose group. The reduced dose group had a 44% reduction in total DLP and 42% reduction in total CTDIvol (p < 0.001). The estimated skin doses were 384 mGy for the full dose group and 224 mGy for the reduced dose group (42% reduction) (p < 0.001). At 12-month follow-up, the technical success for the full dose (n=62) was 97% with 2 patients requiring a further cryoablation treatment for residual tumor. The technical success for the reduced dose group (n=41) was 100%.CONCLUSIONCT dose reduction technique during image-guided cryoablation treatment of renal tumors can achieve significant radiation dose reduction whilst maintaining sufficient image quality.Renal cell carcinoma is the most common kidney cancer and has a rising incidence (1–4), with obesity and smoking being major risk factors (5–8).Image-guided ablation offers a more minimally invasive option compared with surgery and the current evidence base shows that it is a safe and effective treatment for T1a tumors, with a low rate of complications (9–11). The major advantage of cryoablation over other modalities is the ability to accurately visualize the iceball and therefore zone of ablation on intraprocedural imaging, either with computed tomography (CT) or magnetic resonance imaging (MRI) (12, 13). However, renal cryoablation involves the placement of more ablation probes and can have almost three times the radiation exposure compared with CT-guided radiofrequency ablation procedures (14).In addition to this substantial radiation dose per cryoablation, estimated to be between 32 and 39.7 mSv, the follow-up CT imaging will also add to the total radiation burden (15, 16). Whilst this level of radiation dose and associated stochastic risk may be a lesser concern in the older patients, greater consideration needs to be given to younger patients (<50 years old) and in patients requiring lifelong follow-up imaging, in particular those with hereditary diseases such as Von Hippel-Lindau syndrome (15). To our knowledge, the potential for reducing radiation dose for cryoablation patients.The principle aim of this study was to evaluate the effect on the radiation dose to the patient by reducing the tube current during the placement of the ablation needles (reduced dose group) compared with the patient doses delivered when scanning at the standard fully diagnostic level (full dose group) in CT-guided percutaneous cryoablation. 相似文献
9.
10.
Micro‐evolution of the hepatitis B virus genome in hepatitis B e‐antigen‐positive carriers: Comparison of genotypes B and C at various immune stages
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)